Search

Introduction. Creating a new herbal remedy with a mild generalized effect is an urgent task of modern pharmacology and pharmaceutical technology. The dosage form of an innovative medicinal product should take into account its properties, ensure the effectiveness of the drug and ease of intake.Aim. Creation of hard gelatin capsules with a plant composition-dry extract and validation of methods for quantifying the amount of flavonoids for the preparation of draft regulatory documentation.Materials and methods. The physicochemical and technological properties of the developed dry extract, as well as experimental capsule masses, such as mass loss during drying, bulk volume and granulometric composition, flowability, angle of natural slope, compaction, and parameters of the obtained capsules (solubility, disintegration, etc.) were studied according to the methods described in the State Pharmacopoeia of the XIV edition. Methods were developed for quantitative determination of flavonoid content in terms of rutin in dry extract and capsules using differential spectrophotometry, which were validated.Results and discussion. During the study of the experimental dry extract, its high hygroscopicity was found, which worsens its technological properties and complicates the encapsulation process. As a result of the addition of auxiliary substances, such as anhydrous lactose and talc, it was possible to obtain an optimal mass for encapsulation, which served as the basis for the creation of the drug «Sedoflav».Conclusion. On the basis of a dry extract of plant composition capsules «Sedoflavt» were developed, its standardization was produced. Methods for quantifying the amount of flavonoids in terms of rutin in experimental dry extract and capsules have been developed and validated.

Aim. The “PARUS” program included investigation of the analgesic, muscle relaxant and sedative effects of Mydocalm-Richter which acts as central muscle relaxant in patients with myofascial pain syndrome, taking into account its registered indication for use - the hypertonus and cross-striated muscle spasm. Materials and methods. Fifty patients with myofascial trigger points, the mean age of 41.67±11.86 years, have been enrolled in the study. All patients had undergone clinical examination that allowed the diagnosis of myofascial pain syndrome. The intensity of pain syndrome was evaluated using the pain visual analogue scales and McGill pain questionnaire. Visualization of area in spasm and evaluation of blood circulation was carried out using the ultrasound scan of target muscle. In order to objectively evaluate any conceivable hypotensive and sedative effects of Mydocalm-Richter we used the orthostatic test, Schulte’s test for attention span and perfor-mance distribution and Munsterberg’s test for attention discrimination and concentration. Results. The analgesic and muscle relaxant effects of Mydocalm-Richter become apparent by day 3 post-injection, and the muscle relaxation effect is reaching its maximum on day 10 post-injection. Cardiovascular function following administration of Mydocalm-Richter was evaluated using the orthostatic test which revealed good orthostatic tolerance. Single injection of tolperisone hydrochloride possessing a central muscle relaxant activity has no sedative effect and does not influence patient response time. The ultrasound examination data demonstrated the improvement and in some cases restoration of blood circulation in the myofascial trigger points. Conclusion. Clinical study “PARUS” conducted in patients with myofascial pain has demonstrated a positive muscle relaxant and analgesic effect of Mydocalm-Richter that resulted in restoration of peripheral circulation in the myofascial trigger pointsconfirmed by ultrasound examination. An important benefit of this drug product is the absence of sedative effect and arterial hypotension.